drugset / Trial / NCT07315503
An Open-label Study of GC012F in Rheumatoid Arthritis.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is An Open-label Study to Evaluate the Safety and Efficacy of GC012F in Patients with Difficult-to-Treat (D2T) Rheumatoid Arthritis.
Timeline
- Start
- 2027-12
- Primary completion
- 2028-01-15
- Completion
- 2041-01-15
Outcome
Outcome not reported
Stopped (Enrollment): “Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 200000 cells/kg | Other |
| Background | Cyclophosphamide | Other / unclassified | 200 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 20 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |